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To understand the basic radiochemistry of Lu-177 and its application in the 
labelling with various ligands (i.e. DOTA, PSMA-617,PSMA-I&T) for the 
theranostic purposes
Outline
Theranostic and its current application in Nuclear medicine 
Elementary chemistry of the radionuclide Lu-177
Production methods of Lu-177
Why Lu-177 is the current work horse of Theranostics?
 Lu-177 based therapeutic radiopharmaceuticals and their labelling 
methods
Conclusion
References
Theranostic and its current application in 
Nuclear medicine 
Therapy with Diagnostics
Term coined by  John Funkhouser, CEO of PharmaNetics
He used this term to describes his companies model of philosophy of diagnosis  and 
therapy techniques. Use of this term started at the end of last century
Theranostic and its current application in 
Nuclear medicine 
Iodine-131 for Diagnosis and Therapy Samuel M. 
Seidlin in1946
Diagnosis with low dose of Iodine-131 followed by 
therapeutic intervention with large doses for the 
management of thyroid cancer.
Some other terminology also used  for Theranostics:
Theranostics
Targeted radionuclide therapy 
Molecular Imaging 
Molecular therapy
Personalized medicine
Theranostic and its current application in 
Nuclear medicine 
Targeting Mechanisms
Antigen binding
Receptor Mapping
Enzyme Activity
DNA Synthesis
Amino acid transport
Accumulation via a 
shuttle
Accumulation via 
blocked metabolism
Theranostic and its current application in 
Nuclear medicine 
PubMed-derived number of publications including the term theranostic or 
theragnostic during each year from 2001 to 2017 
(search performed July 16, 2017). Ken Herrmann et al. J Nucl Med 2017;58:1S-2S
Elementary chemistry of the radionuclide Lu-177
Elementary chemistry of the radionuclide Lu-177
Discovered in 1907
Discovered by Georges Urbain in Paris, France and 
independently by Charles James in New 
Hampshire, USA Baron Carl Auer von Welsbach 
(Austraian)
Origin of the name The name derives from the Romans' name for 
Paris, 'Lutetia'. “Lutecium””cassiopeium” (or later 
cassiopium, Lutetium came in 1949
Group in Periodic Table Lanthanides
Atomic Number 71
Atomic Mass 174.967 amu
Biological use No known biological role.
It has low toxicity
Oxidation states +3
Key Isotopes Lu-175,Lu-176,Lu-177,Lu-177m 
Elementary chemistry of the radionuclide Lu-177
Quick facts about Lutetium
Physical Data
Radiation Betas
Gamma
490 keV
113 keV (3%),210 keV (11%)
Gamma Constant 0.028 mrem/hr per mCi @ 1.0 meter 
[7.636E-6 mSv/hr per MBq @ 1.0 meter]
Half life Physical
Biological
Effective
6.73 days
GI: ~1 day; Lungs: ~30 days
GI: ~0.9 days; Lungs: ~6 days
Specific Activity 1.1E5 Ci/g [4.1E15 Bq/g] max
Intake Routes Ingestion, inhalation, puncture, wound, skin 
contamination (absorption)
Shielding HVL (For Betas)
HVL (For Gamma)
TVL  (For Gamma)
0.135 cm Plexiglas
0.6 mm (0.02 inches)
2.1 mm (0.08 inches)
Special precaution Avoid skin contamination [absorption], 
ingestion, inhalation, & injection [all routes of 
intake]
Mean tissue penetration 0.7 mm 
Elementary chemistry of the radionuclide Lu-177
Physical characteristics of Lutetium-177
Mostly Produce in Nuclear Reactor.
Few studies reported cyclotron production, but not appropriate for large 
production.
Lutetium-177 is produced in a nuclear reactor either through ‘direct’ method by 
the neutron activation of enriched Lu-176 target, also called as Carrier aided (CA)
‘Indirect’ method of neutron activation of enriched Yb-176 target followed by beta 
decay of Yb-177 to Lu-177, also known as NCA (No carrier Aided).
Production methods of Lu-177
CA (Carrier aided) Lu-177 NCA (No Carrier aided) Lu-177
Lu-176(n,γ) Lu-177 Yb-176(n,γ)Yb-177 ->Lu-177
The specific activity of Lu-177 can be achieved up to 70 
Ci (2590 GBq)/mg, which is less than theoretical required 
specific activity.
The specific activity will be closer to or equivalent to the 
theoretical specific activity of 111.11 Ci (4111 Gbq)/mg of 
Lu-177
Also produce a co-product of Lu-177m which is very long 
lived radionuclide impurity 
No Lu-177m production which keeps the specific activity 
at highest
Easily producible in any nuclear reactor as required 
neutron flux is easily available in all reactors
Requirement of high flux nuclear reactor 
It is highly essential that very efficient chemical separation 
methods are available for separation of the microscopic levels of 
Lu-177 from the macroscopic mass of Yb, otherwise Yb 
contamination will adversely affect the complexation chemistry of 
Lu+3.
Production methods of Lu-177
Production methods of Lu-177
“The metastable isomer lutetium-177m,
which is formed concomitantly during the
production of 177Lu by neutron capture,
is a high-energy nuclear isomer with a
half-life of 160.4 days. 78.6% of 177mLu
decays by beta emission to 177mHf
and 177Hf and 21.4% decays to 177Lu,
the ground state, via isomeric
transition. Isomeric transition can
occur either via internal conversion or
γ-rays emission. Internal conversion is
a radiation less decay where the
excess of nucleus energy is
transferred to an electron in the K- L-
or M- shell. This energy transfer leads to
an Auger electron cascade that results in
a highly charged state ultimately
provoking bond rupture.”Bhardwaj, R., van der Meer, A., Das, S. K., de Bruin, M., Gascon, J., Wolterbeek, H. T., . . . Serra-Crespo, P. (2017). Separation of nuclear 
isomers for cancer therapeutic radionuclides based on nuclear decay after-effects. Scientific Reports, 7, 44242. doi:10.1038/srep44242
https://www.nature.com/articles/srep44242#supplementary-information
(a) Decay scheme of 177mLu to 177Lu. (ii) Process of bond rupture. The metastable isomer 177mLu is coordinated to 
a very stable complex (left side). During the decay via internal conversion the nucleus excess of energy is transferred 
to an inner electron causing an auger electron cascade (center). After the cascade the atom is in a highly charge 
state, the chemical bonds are broken and the freed 177Lu can be separated (right side).
Production methods of Lu-177
 Lu-177 is a medium-energy β-emitter (Emax = 0.490 MeV) with maximal tissue penetration of 1.5
mm, which results in the efficient deposition of the energy in tumour lesions and minimises
damage to surrounding healthy tissue
 Additionally, it emits low-energy γ-rays which allow scintigraphy and subsequent dosimetry with
the same therapeutic compound, making Lu-177 a theranostically-desirable radioisotope
 Lu-177 also have a long enough half-life (6.73 days) which makes easily transportable
radionuclide
 Lu-177 have +3 oxidation states which makes its chemistry easy for chemical reactions to form
bonding
Why Lu-177 is the current work horse of Theranostics?
S.No Name of
Radiopharmaceuticals
Used for Clinical trial conducted by and    
approval stage
1. Lu-177-DOTATATE/TOT/NOC Treatment of  GIP-
Neuroendocrine Tumour
Advance Accelerator 
Applications S.A. /FDA 
APPROVED
2. Lu-177-EDTMP Bone metastasis secondary to 
prostate and breast cancer 
IAEA, India, China, 
Uruguay 
Phase II completed
3. Lu-177-PSMA-617/I&T/J591 Labelled PSMA to treat  
metastatic prostate cancer
Endocyte,USA /Phase II 
completed 
4. Lu-177-Rituximab Treatment of non-Hodgkin
lymphoma
Switzerland/Phase II 
completed
5. Lu-177-CC49 Ovarian cancer USA/Phase II
Lu-177 based therapeutic radiopharmaceuticals and 
their labelling methods
Lu-177 based therapeutic radiopharmaceuticals and 
their labelling methods
Manual method
Semiautomatic method
Automatic method
Lu-177 based therapeutic radiopharmaceuticals and 
their labelling methods
Manual method
Requirements
Buffer(1.20 Gm of Sodium Ascorbate and 300 mg of Ascorbic Acid)
Ultrapure  water
0.9% Normal saline
Heater
Milex GV Filter
25 ml Sterile vacumm vial
Vent needles
1 tubing
Male adaptor
Lu-177 chloride
Ligands ( PSMA-617/PSMA-I&T/DKFZ-617/DOTATOC/DOTATAT)
Lu-177 based therapeutic radiopharmaceuticals and 
their labelling methods
Manual method
Buffer is useful for the setting up pH which should be in the range of 
4.5 to 5
Ascorbic acid helps to minimize the process of radiolysis which 
increase the stability of the final product
Calculation for the amount of buffer is based on the amount of 
number of Lu-177 mole  available
Amount of ligand for the labelling is also calculated based on the 
number of Lu-177 moles available for labelling and atomic mass of  
available ligands 
Lu-177 based therapeutic radiopharmaceuticals and 
their labelling methods
Manual method
Calculation of Number of moles of Lu-177:
Specific activity of the received Lu-177   X Molecular weight  of ligand
Mass number of Lutetium
Calculation of ligand amount required:
Number of moles of Lu-177 X 5
Calculation of Required Buffer amount:
(Ligand volume  + Received volume of Lu-177) x 4
Lu-177 based therapeutic radiopharmaceuticals and 
their labelling methods
Manual method
Steps for the labelling
Ligands (PSMA or DOTA TATE ) requires 13ng/MBq to label with Lu-177 or 
the amount of Lu-177 moles available in the solution
Heater should be set at 90 degree
Transfer Buffer solution (of Sodium Ascorbate and Ascorbic acid) to the vial 
containing required amount of peptide
Transfer the mixture of buffer and peptide to a syringe and push this syringe 
to the vial of Lu-177  and remove the syringe
Keep this vial for the heater bath for 30 minutes at 90 degree
Once heating done allow vial to cool for 10 minutes and then do the 
purification with the help of Filter
Quality of the final product must be checked with Thin layer 
chromatography (TLC)  and HPLC 
Lu-177 based therapeutic radiopharmaceuticals and 
their labelling methods
Manual method
Lu-177 based therapeutic radiopharmaceuticals and 
their labelling methods
Manual method
Negatives
Radiation exposure burden for the handler
Time consuming (90-120 minutes)
Positives
Comparable yield with Automatic labelling methods 
(>98%)
Cost effective
Lu-177 based therapeutic radiopharmaceuticals and 
their labelling methods
Semiautomatic method
Requirements
Buffer(1.20 Gm of Sodium Ascorbate and 300 mg of 
Ascorbic Acid)
Ultrapure  water
0.9% Normal saline
Lu-177 chloride
Ligands ( PSMA-617/PSMA-I&T/DKFZ-
617/DOTATOC/DOTATAT)
Semiautomatic synthesizer (i.e. ADD-2)
Lu-177 based therapeutic radiopharmaceuticals 
and their labelling methods
Semiautomatic method
(a) The delivery vial was placed in the ADD shielding
(b) precursor and buffer were added
(c) syringe was discharged
(d) vial transferred on the heating block (set at 90 degree)
(e) placed again in the ADD-2 body after heating
Lu-177 based therapeutic radiopharmaceuticals and 
their labelling methods
Semiautomatic method
Negatives
Still requirement of doing preparation and calculation for 
the labelling which can cause error
Not very cost effective due to the cost involved for 
synthesizer
Positives
Comparable yield with Automatic labelling methods 
(>95%)
Not very time consuming
Lu-177 based therapeutic radiopharmaceuticals and 
their labelling methods
Automatic method
Requirements
Modular-Lab Eazy automatic  Synthesizer
Disposable cassettes (C0-YDOTAPEPCM, C0-LUDOTAPEP-CM, C0-YDOTAPSMA-CM, and C0-LUDOTAPSMA-CM)
Hardware, and reagent kits were supplied by
Lu-177 chloride
Ligands ( PSMA-617/PSMA-I&T/DKFZ-617/DOTATOC/DOTATAT)
Lu-177 based therapeutic radiopharmaceuticals and 
their labelling methods
Automatic method
Requirements
Reagents kits 
Vial 1 (50mL of isotonic saline solution; 0.9% sodium chloride), 
Vial 2 (50mL of water for injection)
Vial 3 (50mg of ascorbic acid)
Hardware kits 
Sterile syringe
Vent needles
Vacuum vial
Cation exchange CM cartridge
Lu-177 based therapeutic radiopharmaceuticals and 
their labelling methods
Automatic method
Image credit  Eckert and Ziegler
Lu-177 based therapeutic radiopharmaceuticals 
and their labelling methods
a) disposable cassette
b) disposable cassettes assembled onto the 
system
c) 1.  Delivery vial 177Lu-chloride solutions)
2.  reagent vial (precursor and buffer 
solution)
3.  reactor vial 
4. waste vial 
5. 0.9% NaCl solution vial
6. product vial 
lori, M., Capponi, P. C., Rubagotti, S., Esposizione, L. R., Seemann, J., Pitzschler, R., . . . Asti, M. (2017). Labelling of (90)Y- and (177)Lu-DOTA-
Bioconjugates for Targeted Radionuclide Therapy: A Comparison among Manual, Semiautomated, and Fully Automated Synthesis. Contrast Media Mol
Imaging, 2017, 8160134. doi:10.1155/2017/8160134
Lu-177 based therapeutic radiopharmaceuticals and 
their labelling methods
Automatic method
Image credit  Eckert and Ziegler
Lu-177 based therapeutic radiopharmaceuticals and 
their labelling methods
Automatic  method
Negatives
Cost effective
Too much of reliability on the system can affect labelling
Positives
High yield with high Radionuclide purity
Less radiation burden for the user
Lu-177 based therapeutic radiopharmaceuticals  based 
treatment outcomes
Lu-177 based therapeutic radiopharmaceuticals  
based outcomes
Lu-177 based therapeutic radiopharmaceuticals  based 
outcomes
68Ga-DOTATATE 
Pre-therapy scan
68Ga-DOTATATE 
Post-therapy scan 
177Lu-DOTATATE 
Therapy Cycle - I
177Lu-DOTATATE 
Therapy Cycle - II
Image credit to Hinduja Hospital,Mumbai,India
(J Kwekkeboom et al.,2010)
Lu-177 based therapeutic radiopharmaceuticals  
based outcomes
Lu-177 based therapeutic radiopharmaceuticals  based  
treatment outcomes
Lu-177 based therapeutic radiopharmaceuticals  based  
treatment outcomes
At 2nd Lu-177-PSMA therapyAt 1st Lu-177-PSMA therapyPre therapy Ga-68-PSMA Scan Post therapy Ga-68-PSMA Scan
Images credit: Mercy Radiology,2019
Fendler WP, Reinhardt S, Ilhan H, et al. Preliminary experience with dosimetry, response and patient 
reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate 
cancer. Oncotarget. 2017;8(2):3581–3590. doi:10.18632/oncotarget.12240
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QOL outcome, at our clinical site
A B C D E F
QoL, Pain and PSA levels; relative comparison
A,B,C,D,E and F stands here for the patients 
treated with Lu-177-PSMA-I&T 
PSA response to Lu-177-PSMA, at our clinical site
Conclusion
Lu-177 is the current work horse of theranostics  due to its characteristic of 
emitting both beta and gamma radiation
Production is mainly reactor based; concept of generator which is based on decay 
of Lu-177m/Lu-177 is recently introduced
Manual/semiautomatic  and automatic methods currently in use but Automatic is 
mainly recommended due to its various benefits
Lu-177 Labelled radiopharmaceuticals (i.e. PSMA-617/DOTATAT/TOC) found very 
useful in the treatment of the patient to improve their overall QoL
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